MP
HZNP

Mangrove Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Mangrove Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-195,308
Closed -$20.1M – 227
2023
Q2 		$20.1M Buy
+195,308
New +$20.6M 1.39% 25

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mangrove Partners's HZNP Position: Q3 2023 in Review

Mangrove Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 195,308 shares — an estimated $20.1M sold.

Mangrove Partners first reported a position in HZNP in Q2 2023 and held it in 1 quarter. The position peaked at $20.1M in Q2 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Mangrove Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Mangrove Partners sold 195,308 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $20.1M.
  • Mangrove Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023 and held it in 1 quarter.
  • Mangrove Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $20.1M in Q2 2023.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Mangrove Partners's 13F filing for Q3 2023, filed 14 Nov 2023.